GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study

BACKGROUND: There is lack of evidence about systemic treatment of pseudomyxoma peritonei (PMP) relapsing after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. There is also lack of biomarkers able to predict outcomes beyond known clinical and pathological prognostic features. ME...

Full description

Saved in:
Bibliographic Details
Published in:J Transl Med
Main Authors: Pietrantonio, Filippo, Berenato, Rosa, Maggi, Claudia, Caporale, Marta, Milione, Massimo, Perrone, Federica, Tamborini, Elena, Baratti, Dario, Kusamura, Shigeki, Mariani, Luigi, Niger, Monica, Mennitto, Alessia, Gloghini, Annunziata, Bossi, Ilaria, Settanni, Giulio, Busico, Adele, Bagnoli, Pietro Francesco, Di Bartolomeo, Maria, Deraco, Marcello, de Braud, Filippo
Format: Artigo
Language:Inglês
Published: BioMed Central 2016
Subjects:
Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4859944/
https://ncbi.nlm.nih.gov/pubmed/27154293
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-016-0877-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items